Advertisement
Research Article| Volume 16, ISSUE 2, P465-491, June 1996

Interferon and Other Therapies for Hepatitis B and Hepatitis C Infections

  • Kenneth D. Rothstein
    Correspondence
    Address reprint requests to: Santiago J. Munoz, MD, Albert Einstein Medical Center, Klein Professional Building, Suite 509, 5401 Old York Road, Philadelphia, PA 19141
    Affiliations
    From the Center for Liver Diseases, and the Department of Medicine, Albert Einstein Medical Center, Temple University School of Medicine, Philadelphia, Pennsylvania
    Search for articles by this author
  • Santiago J. Munoz
    Affiliations
    From the Center for Liver Diseases, and the Department of Medicine, Albert Einstein Medical Center, Temple University School of Medicine, Philadelphia, Pennsylvania
    Search for articles by this author
DOI:https://doi.org/10.1016/S0272-2712(18)30280-4
Interferon and Other Therapies for Hepatitis B and Hepatitis C Infections
Previous ArticleHepatitis Delta Virus: Genetics and Pathogenesis
Next ArticlePrevention of Liver Cancer and Cirrhosis by Vaccines
      This paper is only available as a PDF. To read, Please Download here.
      Interferon is currently the only approved medication in the United States for treatment of chronic hepatitis B and C infections. The mechanism of action of interferon and guidelines for its administration are reviewed. Important clinical studies involving its use in hepatitis B and C infections are discussed, and investigational therapies for chronic viral hepatitis are highlighted.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Clinics in Laboratory Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Abecassis M.
        • Falk J.A.
        • Makowka L.
        • et al.
        16, 16 dimethyl prostaglandin E2 prevents the development of fulminant hepatitis and blocks the induction of monocyte/ macrophage procoagulant activity after murine hepatitis virus strain 3 infection.
        J Clin Invest. 1987; 80: 881
        • Agnello V.
        • Chung R.T.
        • Kaplan L.M.
        A role of hepatitis C infection in type II cryoglobulinemia.
        N Engl J Med. 1992; 327: 1480
        • Alexander G.J.M.
        • Brahm J.
        • Fagan E.A.
        • et al.
        Loss of HBsAg with interferon therapy in chronic hepatitis B virus infection.
        Lancet. 1987; 1: 66
        • Alexander G.
        • Williams R.
        Antiviral treatment in chronic infection with hepatitis B virus.
        Br Med J. 1986; 292: 915
        • Alter M.J.
        • Mast E.E.
        The epidemiology of viral hepatitis in the United States.
        Gastroenterol Clin North Am. 1994; 23: 437
        • Alter M.J.
        • Sampliner R.E.
        Hepatitis C and miles to go before we sleep.
        N Engl J Med. 1989; 321: 1538
        • Andreone P.
        • Cusaro C.
        • Gasbarrini G.
        • et al.
        Pilot study of interferon and ketoprofen combined therapy in non-responder patients with chronic hepatitis C. An interim report.
        Gastroenterology. 1994; 106: 859A
        • Andreone P.
        • Cusaro C.
        • Gasbarrini G.
        Interferon-a increases prostaglandin E2 production by cultured liver biopsy in patients with chronic viral hepatitis: Can non-steroidal anti-inflammatory drugs improve the therapeutic response to interferon?.
        J Hepatol. 1993; 19: 228
        • Andreone P.
        • Cusaro C.
        • Gasbarrini G.
        • et al.
        Alpha-interferon plus indomethacin combined therapy for non-responders patients with chronic hepatitis C.
        Hepatology. 1993; 18: 659
        • Bacon B.R.
        • Rebholz A.E.
        • Fried M.
        • et al.
        Beneficial effect of iron reduction therapy in patients with chronic hepatitis C who failed to respond to interferon.
        Hepatology. 1993; 18: 150A
        • Barreca T.
        • Corsini G.
        • Franceschini R.
        • et al.
        Lichen planus induced by interferon-alpha-2a therapy for chronic hepatitis.
        Eur J Gastroenterol Hepatol. 1995; 7: 367
        • Bassendine M.F.
        • Chadwick R.G.
        • Salmerson J.
        • et al.
        Adenine arabinoside therapy in HBsAg-positive chronic liver disease: A controlled study.
        Gastroenterology. 1981; 80: 1016
        • Bellary S.
        • Smith D.G.
        • Bankes P.
        • et al.
        High dose interferon alpha-2b for chronic hepatitis C. An open label study of the response and predictors of response.
        Am J Gastroenterol. 1995; 90: 259
        • Beloqui O.
        • Prieto J.
        • Suarez M.
        • et al.
        N-acetyl cysteine enhances the response to interferon-alpha in chronic hepatitis C. A pilot study.
        J Interferon Res. 1993; 13: 279
        • Bevers U.
        • Spengler V.
        • Knis W.
        • et al.
        Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: A placebo-controlled trial.
        Hepatology. 1992; 16: 702
        • Black M.
        • Peters M.
        Alpha-interferon treatment of chronic hepatitis C: Need for accurate diagnosis in selecting patients.
        Ann Intern Med. 1992; 116: 86
        • Bodenheimer H.C.
        • Lindsay K.
        • Davis G.
        • et al.
        Ribavirin treatment of chronic hepatitis C.
        Hepatology. 1994; 20: 207A
        • Boker K.H.
        • Ringe B.
        • Kruger M.
        • et al.
        Prostaglandin E plus famciclovir—a new concept for the treatment of severe hepatitis B after liver transplantation.
        Transplantation. 1994; 57: 1706
        • Bonavita M.S.
        • Franco A.
        • Parol M.
        • et al.
        Normalization of depressed natural killer activity after interferon-alpha therapy is associated with a low frequency of relapse in patients with chronic hepatitis C.
        Int J Tissue React. 1993; 15: 11
        • Boucher E.
        • Jouanolle H.
        • Andre P.
        • et al.
        Interferon and ursodeoxycholic acid combined therapy in the treatment of chronic viral C hepatitis: Results from a controlled randomized trial in 80 patients.
        Hepatology. 1995; 21: 322
        • Brillanti S.
        • Carson J.
        • Foli M.
        • et al.
        A pilot study of combination therapy with ribavirin plus interferon-alpha for resistant chronic hepatitis C.
        Gastroenterology. 1994; 107: 812
        • Brillanti S.
        • Levantesi F.
        • Foli M.
        • et al.
        Need for HCV-DNA detection and liver biopsy in anti-HCV positive patients with normal ALT.
        Hepatology. 1994; 20: 235A
        • Bryson Y.
        Effects of interferon on host resistance to viral infection.
        Ann Intern Med. 1982; 96: 80
        • Camps J.
        • Garcia N.
        • Riezv-Boj J.I.
        • et al.
        Ribavirin in the treatment of chronic hepatitis C unresponsive to alpha interferon.
        J Hepatol. 1993; 19: 408
        • Casavilla A.
        • Mateo R.
        • Rakela J.
        • et al.
        Impact of hepatitis C virus (HCV) infection on survival following primary liver transplantation (OLTX) under FK506.
        Hepatology. 1994; 20: 133A
        • Choo Q.L.
        • Kuo G.
        • Weiner A.J.
        • et al.
        Isolation of a CDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome.
        Science. 1989; 244: 359
        • Civitico G.
        • Wang Y.Y.
        • Luscombe C.
        • et al.
        Antiviral strategies in chronic hepatitis B virus infection II. infection of duck hepatitis B virus in vitro using conventional antiviral agents and supercoiled DNA active compounds.
        J Med Virol. 1990; 31: 90
        • Clossegros P.
        • Pouteil-Noble C.
        • Causse X.
        • et al.
        Ganciclovir is an effective antiviral agent for post transplant chronic HBV infections but maintenance therapy is required.
        J Hepatol. 1992; 16: 59
        • Colledan M.
        • Gislon M.
        • Doglia M.
        • et al.
        Liver transplantation in patients with viral B hepatitis and delta infection.
        Transplant Proc. 1987; 21: 4073
        • Colombo C.
        • Setdell K.R.
        • Podds M.
        • et al.
        Effects of ursodeoxycholic acid therapy for liver disease associated with cystic fibrosis.
        J Pediatr. 1990; 117: 482
        • Davies S.E.
        • Portman B.C.
        • O’Grady J.O.
        • et al.
        Hepatic histological findings after transplantation for chronic hepatitis B infection including a unique pattern of fibrosing cholestatic hepatitis.
        Hepatology. 1991; 13: 150
        • Davis G.L.
        Chronic hepatitis.
        in: Kaplowitz N Liver and Biliary Diseases, vol 1. Williams & Wilkins, Baltimore1992
        • Davis G.L.
        • Baiart L.A.
        • Schiff E.R.
        • et al.
        Treatment of chronic hepatitis C with recombinant interferon alpha.
        N Engl J Med. 1989; 321: 1501
        • Davis G.L.
        • Hoofnagle J.H.
        Interferon in viral hepatitis: role in pathogenesis and treatment.
        Hepatology. 1986; 6: 1038
        • De la Mata M.
        • Montero J.
        • Friga E.
        • et al.
        Efficiency of ganciclovir in the treatment of hepatitis B virus infection of the liver graft. Long-term results.
        Hepatology. 1995; 22: 130A
        • DeCaestecer J.S.
        • Jazrawi R.P.
        • Petroni M.L.
        • et al.
        Ursodeoxycholic acid in chronic liver disease.
        Gut. 1991; 32: 1061
        • DiBisceglie A.M.
        Liver transplantation for hepatitis C: the promise and the challenge.
        Hepatology. 1995; 22: 660
        • DiBisceglie A.M.
        • Fried M.W.
        • Swain M.G.
        • et al.
        Randomized, double-blind placebo controlled trial of ribavirin therapy for chronic hepatitis C.
        Hepatology. 1993; 18: 145A
        • DiBisceglie A.M.
        • Fong T.L.
        • Fried M.W.
        • et al.
        A randomized, controlled trial of recombinant alpha-interferon therapy for chronic hepatitis B.
        Am J Gastroenterol. 1993; 88: 1887
        • DiBisceglie A.M.
        • Martin P.
        • Kassianides C.
        • et al.
        Recombinant interferon alpha therapy for chronic hepatitis C.
        N Engl J Med. 1989; 321: 1506
        • Dienstag J.L.
        • Perrillo R.P.
        • Schiff E.R.
        • et al.
        A preliminary trial of Lamivudine for chronic hepatitis B infection.
        N Engl J Med. 1995; 333: 1657
        • DiBisceglie A.M.
        • Shindo M.
        • Feng T.
        • et al.
        A pilot study of ribavirin therapy for chronic hepatitis C.
        Hepatology. 1992; 16: 649
        • Dongworth D.W.
        • McMichael A.J.
        Inhibition of human T lymphocyte function with monoclonal antibodies.
        Br Med Bull. 1984; 40: 254
        • Dooley J.S.
        • Davis G.L.
        • Peters M.
        • et al.
        Pilot study of recombinant alpha interferon for chronic type B hepatitis.
        Gastroenterology. 1986; 90: 150
        • Dousset B.
        • Conti F.
        • Houssin D.
        • et al.
        Acute vanishing bile duct syndrome after interferon therapy for recurrent HCV infection in liver transplant recipients [letter].
        N Engl J Med. 1994; 330: 1161
        • Dusheiko G.
        • DiBisceglie A.
        • Bowyer S.
        • et al.
        Prolonged recombinant leucocyte interferon treatment of chronic hepatitis B.
        Hepatology. 1985; 5: 556
        • Dusheiko G.
        • Hoofnagle J.H.
        Hepatitis B.
        in: McIntyre N Benhamox JP Oxford Textbook of Clinical Hepatology, vol 1. Oxford University, Oxford1991
        • Feitelson M.A.
        • Duan L.X.
        • Guo J.
        • et al.
        X region deletion variants of hepatitis B virus in surface antigen-negative infections and non-A, non-B hepatitis.
        J Infect Dis. 1995; 172: 713
        • Feitelson M.A.
        • Lega L.
        • Guo J.
        • et al.
        Pathogenesis of posttransfusion viral hepatitis in children with beta-thaleissemia.
        Hepatology. 1994; 19: 558
        • Feray C.
        • Samuel D.
        • Gigou M.
        • et al.
        An open trial of interferon alpha recombinant for hepatitis C after liver transplantation: Antiviral effects and risk of rejection.
        Hepatology. 1995; 22: 1084
        • Ferell L.D.
        • Wright T.L.
        • Roberts J.
        • et al.
        Hepatitis C viral infection in liver transplant recipients.
        Hepatology. 1992; 16: 865
        • Ferri C.
        • Marzo E.
        • Longobardo G.
        • et al.
        Interferon-alpha in mixed cryoglobulinemia patients: Randomized, crossover controlled trial.
        Blood. 1993; 81: 1132
        • Flowers M.
        • Sherker A.
        • Sinclair S.B.
        • et al.
        Prostaglandin E in the treatment of recurrent hepatitis B infection after orthotopic liver transplantation.
        Transplantation. 1994; 58: 183
        • Fried M.W.
        • DiBisceglie A.M.
        • Straus S.E.
        • et al.
        FIAU, a new oral anti-viral agent, profoundly inhibits HBV DNA in patients with chronic hepatitis B.
        Hepatology. 1992; 16: 127A
        • Fried M.W.
        • Hoofnagle J.H.
        Therapy of hepatitis C.
        Semin Liver Dis. 1995; 15: 82
        • Fried R.H.
        • Murakami C.S.
        • Fisher L.D.
        • et al.
        Ursodeoxycholic acid treatment of refractory chronic graft-versus-host disease of the liver.
        Ann Intern Med. 1992; 116: 624
        • Gallorini A.
        • Plebani M.
        • Pontsso P.
        • et al.
        Serum markers of hepatic fibrogenesis in chronic hepatitis type C treated with alfa-2a interferon.
        Liver. 1994; 14: 257
        • Gaudin J.L.
        • Faure P.
        • Godinot H.
        • et al.
        The French experience of treatment of chronic type D hepatitis with a 12 month course of interferon alpha-2b. Results of a randomized controlled trial.
        Liver. 1995; 15: 45
        • Giannelli G.
        • Antonelli G.
        • Fera F.
        • et al.
        2′, 5′-01igoadenylate synthetase activity as a responsive marker during interferon therapy for chronic hepatitis C.
        J Interferon Res. 1933; 13: 57
        • Gish R.G.
        • Imperial J.I.
        • Esquivel C.O.
        • et al.
        Ganciclovir treatment of severe hepatitis B virus (HBV) infection.
        Gastroenterology. 1993; 104: A908
        • Goodgame R.W.
        Gastrointestinal cytomegalovirus disease.
        Ann Intern Med. 1993; 119: 924
        • Greenberg H.B.
        • Pollard R.B.
        • Lutwick L.I.
        • et al.
        Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis.
        N Engl J Med. 1976; 295: 517
        • Grelier L.
        • Brown D.
        • McPhilips P.
        • et al.
        Lamivudine prophylaxis: A new strategy for prevention of reinfection in liver transplantation for hepatitis B DNA positive cirrhosis.
        Hepatology. 1995; 22: 224A
        • Gumber S.C.
        • Chopra S.
        Hepatitis C: A multifaceted disease.
        Ann Intern Med. 1995; 123: 615
        • Gutfreund K.S.
        • Fischer K.P.
        • Tipples G.
        • et al.
        Lamivudine results in a complete and sustained suppression of hepatitis B viral replication in patients requiring orthotopic liver transplantation for cirrhosis secondary to hepatitis B.
        Hepatology. 1995; 22: 328A
        • Guyer R.
        • Tiedeman J.
        • Yannuzzi L.A.
        • et al.
        Interferon-associated retinopathy.
        Arch Opthalmol. 1993; 111: 350
        • Hadziyannis S.T.
        • Sherman M.
        • Liberman H.M.
        • et al.
        Liver disease activity and hepatitis B virus replication in chronic delta antigen-positive hepatitis B virus carriers.
        Hepatology. 1985; 5: 544
        • Hagiwara H.
        • Hayashi N.
        • Mita E.
        • et al.
        Quantitative analysis of hepatitis C virus RNA in serum during interferon alpha therapy.
        Gastroenterology. 1993; 104: 877
        • Hanson R.G.
        • Peters M.G.
        • Hoofnagle J.H.
        Effects of immunosuppressive therapy with prednisone on band T lymphocyte function in patients with chronic type B hepatitis.
        Hepatology. 1986; 6: 173
        • Hayashi H.
        • Takikawa T.
        • Nishimura N.
        • et al.
        Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron.
        Am J Gastroenterol. 1994; 89: 986
        • Heron I.
        • Hokland M.
        • Berg K.
        Enhanced expression of beta-2 microglobulin and HLA antigens on human lymphoid cells by interferon.
        Proc Natl Acad Sei USA. 1978; 75: 6215
        • Honkoop P.
        • deMan R.A.
        • Zondenan P.E.
        • et al.
        Histologic improvement in patients with chronic hepatitis B virus infection treated with lamivudine is associated with a decrease in HBV-DNA by PCR.
        Hepatology. 1995; 22: 328A
        • Hoofnagle J.H.
        • Davis G.L.
        • Pappas S.C.
        • et al.
        A short course of prednisolone in chronic type B hepatitis: Report of a randomized, double-blind, placebo-controlled trial.
        Ann Intern Med. 1986; 104: 1
        • Hoofnagle J.H.
        • DiBisceglie A.M.
        • Waggoner J.G.
        • et al.
        Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B.
        Gastroenterology. 1993; 104: 1116
        • Hoofnagle J.H.
        • Hanson R.G.
        • Minuk O.Y.
        • et al.
        Randomized controlled trial of adenine arabinoside monophosphate for chronic type B hepatitis.
        Gastroenterology. 1984; 86: 150
        • Hoofnagle J.H.
        • Mullen K.D.
        • Jones D.B.
        • et al.
        Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon.
        N Engl J Med. 1986; 315: 1575
        • Hoofnagle J.H.
        • Peters M.
        • Muller K.D.
        • et al.
        Randomized controlled trial of recombinant human alpha interferon in patients with chronic hepatitis B.
        Gastroenterology. 1988; 95: 1318
        • Hopf V.
        • Neuhaus P.
        • Lobeck H.
        • et al.
        Follow-up of recurrent hepatitis B and delta infection in liver allograft recipients after treatment with recombinant interferon alpha.
        J Hepatol. 1991; 13: 339
        • Hsu H.Y.
        • Chang M.H.
        • Hsieh K.H.
        • et al.
        Cellular immune response to HbeAg in mother-to-infant transmission of hepatitis B virus.
        Hepatology. 1992; 15: 770
        • Jacobs J.M.
        • Martin P.
        • Munoz S.J.
        • et al.
        Liver transplantation for chronic hepatitis B in Asian males.
        Transplant Proc. 1993; 25: 1904
        • Johnson H.M.
        • Bazer F.W.
        • Szente B.E.
        • et al.
        How interferons fight disease.
        Sei Am. 1994; 5: 68
        • Johnson R.J.
        • Gretch D.R.
        • Couser W.G.
        • et al.
        Hepatitis C virus associated glomerulonephritis. Effect of alpha-interferon therapy.
        Kidney Int. 1994; 46: 1700
        • Kasahara A.
        • Hayashi N.
        • Hiramatsu N.
        • et al.
        Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: A multicenter randomized controlled trial.
        Hepatology. 1995; 21: 291
        • Korenman J.
        • Baker B.
        • Waggoner J.
        • et al.
        Long-term remission of chronic hepatitis B after alpha-interferon therapy.
        Ann Intern Med. 1991; 114: 629
        • Koziel M.J.
        • Dudley D.
        • Afdhal N.
        • et al.
        Hepatitis C virus (HCV)—specific cytotoxic T lymphocytes recognize epitopes in the core and envelope proteins of HCV.
        J Virology. 1993; 67: 7522
        • Kruger M.
        • Tillmann H.L.
        • Trautwein C.
        • et al.
        Famciclovir treatment of hepatitis B virus recurrence after orthotopic liver transplantation—a pilot study.
        Hepatology. 1995; 22: 219A
        • Lai C.L.
        • Lin H.J.
        • Lau J.Y.N.
        • et al.
        Effect of recombinant alpha 2 interferon with or without prednisone in Chinese HBsAg carrier children: A prospective double-blind controlled trial.
        Q J Med. 1991; 78: 155
        • Lake J.R.
        Liver transplantation for patients with hepatitis B: What have we learned from our results?.
        Hepatology. 1991; 13: 796
        • Lega L.
        • Vierucci A.
        • Blumberg B.S.
        • et al.
        Hepatitis B x antigen and polymerase antibodies in the serum of hepatitis B carriers with or without delta virus infection. Effects of the interferon treatment.
        J Hepatology. 1992; 14: 286
        • Liaw Y.F.
        • Sheer I.S.
        • Lin S.M.
        • et al.
        Effects of prednisone pre-treatment in interferon alpha therapy for patients with chronic non-A, non-B (c) hepatitis.
        Liver. 1993; 13: 46
        • Lindor K.D.
        • Barnes J.
        Ursodeoxycholic acid for the treatment of home parenteral nutrition-associated cholestasis. A case report.
        Gastroenterology. 1991; 101: 250
        • Locarnin S.
        • Guo K.
        • Lucas R.
        • et al.
        Inhibition of HBV DNA replication of ganciclovir in patients with AIDS.
        Lancet. 1989; 2: 1225
        • Lok A.S.F.
        Antiviral therapy of the asian patient with chronic hepatitis B.
        Semin Liver Dis. 1993; 13: 360
        • Lok A.S.F.
        • Lai C.L.
        • Leung E.K.Y.
        Interferon antibodies may negate the antiviral effects of recombinant alpha-interferon treatment in patients with chronic hepatitis B infection.
        Hepatology. 1990; 12: 1266
        • Lok A.S.F.
        • Lai C.L.
        • Wu P.C.
        • et al.
        Long-term follow-up in a randomized controlled trial of recombinant alpha-interferon in patients with chronic hepatitis B infection.
        Lancet. 1988; 2: 298
        • Mahaney K.
        • Tedeschi V.
        • Maertens G.
        • et al.
        Genotypic analysis of hepatitis C virus in American patients.
        Hepatology. 1994; 20: 1405
        • Marcellin P.
        • Samuel D.
        • Areias J.
        • et al.
        Pretransplantation interferon treatment and recurrence of hepatitis B virus infection after liver transplantation for hepatitis B related end stage liver disease.
        Hepatology. 1994; 19: 6
        • Martin P.
        • Hann H.
        • Westerberg S.
        • et al.
        Prospective, controlled trial of interferon-alpha for chronic hepatitis B in Asian-Americans.
        Gastroenterology. 1995; 108: A1118
        • Martin P.
        • Munoz S.J.
        • DiBisceglie A.M.
        • et al.
        Recurrence of hepatitis C virus infection following orthotopic liver transplantation.
        Hepatology. 1991; 13: 719
        • Maynard J.E.
        • Kane M.A.
        • Alter H.J.
        • et al.
        Control of hepatitis B by immunization: Global perspectives.
        in: Zuckerman AJ Viral Hepatitis and Liver Diseases. Liss, New York1988
        • Maynard J.E.
        • Kane M.A.
        • Hadler S.C.
        Global control of hepatitis B through immunization: Role of hepatitis B in the expanded program on immunization.
        Rev Infect Dis. 1989; 2: 574
        • McKenzie R.
        • Fried M.W.
        • Sallie R.
        • et al.
        Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B.
        N Engl J Med. 1995; 333: 1099
        • McMahon G.
        • Ehrlich P.H.
        • Moustafa Z.A.
        • et al.
        Genetic alterations in the gene encoding the major HBsAg: DNA and immunological analysis of recurrent HbsAg derived from monoclonal antibody-treated liver transplant patients.
        Hepatology. 1992; 15: 757
        • Mion F.
        • Boillot O.
        • Gille D.
        • et al.
        Liver transplantation for posthepatic B delta cirrhosis: Prevention of recurrence with high dose anti-HBs immunoglobulins.
        Transplant Proc. 1993; 25: 2638
        • Misiani R.
        • Bellavita P.
        • Fenili D.
        • et al.
        Hepatitis virus infection in patients with essential mixed cryoglobulinemia.
        Ann Intern Med. 1992; 117: 573
        • Misiani R.
        • Bellavita P.
        • Fenili D.
        • et al.
        Interferon alpha-2a therapy in cryoglobulinemia associated with hepatitis C virus.
        N Engl J Med. 1994; 330: 751
        • Mita E.
        • Hayashi N.
        • Hagiwara H.
        • et al.
        Predicting interferon therapy efficacy from hepatitis C virus genotype and RNA titer.
        Dig Dis Sei. 1994; 39: 977
        • Muller R.
        • Gubernatis G.
        • Farle M.
        • et al.
        Liver transplantation in HBs antigen (HBsAg) carriers: Prevention of hepatitis B (HBV) recurrence by passive immunization.
        J Hepatol. 1991; 13: 339
        • Nair P.V.
        • Tong M.J.
        • Stevenson D.
        • et al.
        A pilot study on the effects of prednisone withdrawal on serum hepatitis B virus DNA and HBeAg in chronic active hepatitis B.
        Hepatology. 1986; 6: 1319
        • Neuhaus P.
        • Blumhardt G.
        • Bechstein W.
        • et al.
        Liver transplantation in HBsAg patients with short and long term immunoprophylaxis.
        Hepatology. 1991; 18: 58A
        • Niv J.
        • Wang Y.
        • Dixon R.
        • et al.
        The use of ampligen alone and in combination with ganciclovir and coumermycin Al for the treatment of ducks congenitally infected with duck hepatitis B virus.
        Antiviral Res. 1993; 21: 155
        • Okada S.
        • Akahane I.
        • Suzuki H.
        • et al.
        The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients.
        Hepatology. 1992; 16: 619
        • Olynyk J.
        • Reddy R.
        • DiBisceglie A.M.
        • et al.
        Hepatic iron concentration as a predictor of response to alpha interferon therapy in chronic hepatitis C.
        Hepatology. 1993; 18: 90A
        • Olynyk J.
        • Reddy R.
        • DiBisceglie A.M.
        • et al.
        Improvement of serum aminotransferase levels after phlebotomy in patient with chronic active hepatitis C and excess hepatic iron.
        Am J Gastroenterol. 1994; 89: 986
        • Ouzan D.
        • Gugenheim J.
        • Crafa F.
        • et al.
        Long-term passive immunoprophylaxis of B virus recurrence after liver transplantation in HBs antigen-positive patients.
        Hepatology. 1992; 16: 287A

      116. Paar DP, Hooten TM, Smiles KA, et al: The effects of FIAU on chronic hepatitis B virus (HBV) infection in HIV infected subjects (ACTG 122b) [abstract 264A]. In Programs and Abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, 1992

        • Papo T.
        • Marcellin P.
        • Bernavau J.
        • et al.
        Autoimmune chronic hepatitis exacerbated by alpha-interferon.
        Ann Intern Med. 1992; 116: 51
        • Patterson J.L.
        • Femandez-Larson R.
        Molecular mechanisms of action of ribavirin.
        Rev Infect Dis. 1990; 12: 1139

      119. Perez R, Pravia R, Linares A, et al: Response related factors in recombinant interferon alpha-2b treatment of chronic hepatitis C. Gut S 139, 1993

        • Perillo R.P.
        • Regenstein F.G.
        • Bodicky C.J.
        • et al.
        Comparative efficacy of adenine arabino-side 5′ monophosphate and prednisone withdrawal followed by adenine 5 monophosphate in the treatment of chronic active hepatitis type B.
        Gastroenterology. 1985; 88: 780
        • Perillo R.P.
        • Regenstein F.G.
        • Peters M.G.
        • et al.
        Prednisone withdrawal followed by recombinant alpha interferon in the treatment of chronic type B hepatitis.
        Ann Intern Med. 1988; 109: 95
        • Perillo R.P.
        • Schiff E.R.
        • Davis G.L.
        • et al.
        A randomized controlled trial of interferon alpha-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis.
        N Engl J Med. 1990; 323: 295
        • Peters M.
        • Davis G.L.
        • Dooley J.S.
        • et al.
        The interferon system in acute and chronic viral hepatitis.
        in: Popper H Schnaffner F Progress in Liver Diseases, vol 8. Grune & Stratton, New York1986
        • Piperno A.
        • D’Alba R.
        • Roffi L.
        • et al.
        Relation between interferon therapy response to liver iron stores in chronic hepatitis C.
        Hepatology. 1993; 18: 250A
        • Pleuris J.N.
        • Hayes P.C.
        • Bouchier I.A.D.
        Ursodeoxycholic acid in the treatment of alcoholic liver disease.
        Eur J Gastroenterol Hepatol. 1991; 3: 65306
        • Pollard R.P.
        • Smith E.A.
        • Neal E.A.
        • et al.
        Effect on vidarabine on chronic hepatitis B infection.
        JAMA. 1978; 239: 1648
        • Poupon R.E.
        • Balkkau B.
        • Eschwege E.
        • et al.
        UDCA-PBC study group. A multicenter trial of ursodiol for the treatment of primary biliary cirrhosis.
        N Engl J Med. 1991; 324: 1548
        • Poynard T.
        • Bedossa P.
        • Chevallier M.
        • et al.
        A comparison of three interferon alpha-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis.
        N Engl J Med. 1995; 332: 1457
        • Rakela J.
        • Redeker A.G.
        • Weliky B.
        Effect of short term prednisone therapy on aminotransferase levels and hepatitis B virus markers in chronic type B hepatitis.
        Gastroenterology. 1983; 84: 956
        • Rakela J.
        • Tong M.
        • Shiftman M.
        • et al.
        An open-label randomized, parallel evaluation of one, three and six million units of interferon (IFN) alpha-2a in the six month treatment of patients with chronic non-A, non-B hepatitis (NANB).
        Gastroenterology. 1993; 104: A976
        • Reichard O.
        • Anderson J.
        • Schvarez Z.
        • et al.
        Ribavirin treatment for chronic hepatitis.
        Lancet. 1991; 337: 1058
        • Reichard O.
        • Glaumann H.
        • Fryden A.
        • et al.
        Two year biochemical virological and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon alpha-2b treatment.
        Hepatology. 1995; 21: 918
        • Roffi L.
        • Mels G.C.
        • Antonelli G.
        • et al.
        Breakthrough during recombinant interferon alpha therapy in patients with chronic hepatitis C virus infection: Prevalence, etiology and management.
        Hepatology. 1995; 21: 645
        • Rumi M.O.
        • DelNinno E.
        • Romeo R.
        • et al.
        Long-term course of IFN 2b treatment in chronic hepatitis delta.
        Hepatology. 1995; 22: 193A
        • Samuel D.
        • Bismuth A.
        • Mathieu D.
        • et al.
        Passive immuno-prophylaxis after liver transplant in HBsAg-positive patients.
        Lancet. 1981; 337: 813
        • Samuel D.
        • Muller R.
        • Alexander G.
        • et al.
        Liver transplantation in European patients with the hepatitis B surface antigen.
        N Engl J Med. 1993; 329: 1842
        • Sangiovanni A.
        • Spinzi G.C.
        • Morales R.
        • et al.
        Natural history of anti-HCV positive patients with normal transaminases.
        Hepatology. 1994; 20: 395A
        • Schalm S.W.
        • Heijtiak R.A.
        • van Buren H.R.
        • et al.
        Acyclovir enhances the antiviral effect of interferon in chronic hepatitis B.
        Lancet. 1985; 2: 358
        • Shindo M.
        • DiBisceglie A.M.
        • Hoofnagle J.H.
        Long-term follow-up of patients with chronic hepatitis C treated with alpha-interferon.
        Hepatology. 1992; 15: 1013
        • Shouval D.
        • Ilan Y.
        Transplantation of hepatitis B immune lymphocytes as means for adoptive transfer of immunity to hepatitis B virus.
        J Hepatol. 1995; 23: 98
        • Stachura J.
        • Tasnawski A.
        • Ivey K.
        • et al.
        Prostaglandin protection of carbon tetrachloride induced liver cell necrosis in the rat.
        Gastroenterology. 1981; 81: 211
        • Stevens C.E.
        • Deasley R.P.
        • Tsui J.
        • et al.
        Vertical transmission of hepatitis B antigen in Taiwan.
        N Engl J Med. 1995; 292: 771
        • Stewart W.E.
        The Interferon System. ed 2. Springer-Verlag, New York1979
        • Todo S.
        • Demetrias A.J.
        • Van Thiel D.
        • et al.
        Orthotopic liver transplantation for hepatitis B virus related liver disease.
        Hepatology. 1991; 13: 619
        • Van Thiel D.H.
        • Gavler J.S.
        • Wright H.I.
        • et al.
        Responses to interferon therapy are influenced by the iron content of the liver.
        Gastroenterology. 1992; 102: 904
        • Vargas V.
        • Charco R.
        • Castells L.
        • et al.
        Alpha-interferon for acute hepatitis C in liver transplant patients.
        Transplant Proc. 1995; 27: 1222
        • Vitiello A.
        • Ishioka G.
        • Grey H.
        • et al.
        Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Indication of a primary cytotoxic T lymphocyte response in humans.
        J Clin Invest. 1995; 95: 341
        • Weinstein J.S.
        • Poterucha J.J.
        • Rakela J.
        • et al.
        Long-term outcome of hepatitis C (HCV) infected liver transplant (OLT) recipients.
        Hepatology. 1994; 20: 133A
        • WHO Technical Advisory Group on Viral Hepatitis
        Progress in the control of viral hepatitis. Memorandum for a WHO meeting.
        Bull World Health Organ. 1988; 4: 443
        • Wiranowska-Stewart M.
        • Stewart W.E.
        Determination of human leukocyte population involved in the production of interferons alpha and gamma.
        J Interferon Res. 1981; 1: 233
        • Woolf G.M.
        • Villamil F.G.
        • Petrovic L.M.
        • et al.
        Lamivudine therapy of fibrosing cholestatic hepatitis (FCH) due to recurrent hepatitis B virus (HBV) post-liver transplantation (LT).
        Hepatology. 1995; 22: 510A
        • Wright H.I.
        • Gavaler J.S.
        • Van Thiel D.H.
        Preliminary experience with alpha-2b-interferon therapy of viral hepatitis in liver allograft recipients.
        Transplantation. 1992; 53: 121
        • Wu P.C.
        • Lai C.L.
        • Lam K.C.
        • et al.
        Prednisolone in HBsAg-positive chronic active hepatitis: histologic evaluation in a controlled prospective study.
        Hepatology. 1982; 6: 777
        • Yoshioka K.
        • Kakumu S.
        • Wakita T.
        • et al.
        Delection of hepatitis C virus by polymerase chain reaction and response to interferon-alpha therapy: Relationship to genotypes of hepatitis C virus.
        Hepatology. 1992; 16: 293

      Article info

      Identification

      DOI: https://doi.org/10.1016/S0272-2712(18)30280-4

      Copyright

      © 1996 Elsevier Inc. Published by Elsevier Inc. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX